Ezequiel Lerech

Ezequiel Lerech

Auto-generated profile, based on publicly available information

Ezequiel Lerech

Área SAC Joven, Sociedad Argentina de Cardiología

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2025 in Revista Argentina de Cardiologia
Verified
Journal Article
Open access
PDF file
LHLucia Helguera
Lucia Helguera
CCCeleste Carrero
Celeste Carrero
GGGustavo Giunta
Gustavo Giunta
ELEzequiel Lerech
Ezequiel Lerech
JCJuan Pablo Costabel
Juan Pablo Costabel
PSPablo Stutzbach
Pablo Stutzbach
Background: Adherence to statin therapy in secondary cardiovascular prevention remains a clinical challenge. Medical misinformation, especially through digital media, has been identified as a possible contributing factor to this problem. Objective: To describe the reasons for patients' reluctance to use statins in secondary prevention., according to the perception of health professionals in Argentina. Methods: An anonymous and voluntary survey was conducted between March and April 2025, distributed through the Argentine Society of Cardiology, with the participation of 638 health professionals. Data were collected on the frequency and reasons for statin refusal, perception of recent changes, and acceptance of other therapies. Results: A total of 40.9% of respondents reported recent rejection of statins. The main reasons were adverse events (53.4%) and the influence of negative digital information (50.5%). Other factors included advice from third parties, controversial medical indications, economic reasons, and autonomous decisions. Other therapies were accepted by 74% of patients who rejected statins, and 66.6% of professionals noted an increase in this trend. Conclusions: Reluctance to use statins represents a growing threat to cardiovascular prevention in Argentina. The results highlight the impact of medical misinformation on therapeutic decisions. It is essential to implement educational and communication strategies aimed at professionals and patients to reverse this trend.

28 October 2021
Verified
Journal Article
Closed access
ASAlan Rodrigo Sigal
Alan Rodrigo Sigal
MAMelisa Antoniolli
Melisa Antoniolli
PSPilar Lopez Santi
Pilar Lopez Santi
NANicolás Aquino
Nicolás Aquino
ELEzequiel Lerech
Ezequiel Lerech
FBFernando Botto
Fernando Botto

31 October 2021 in Revista Argentina de Cardiologia
Verified
Journal Article
Open access
ASAlan R. Sigal
Alan R. Sigal
MAMelisa Antoniolli
Melisa Antoniolli
PSPilar Lopez Santi
Pilar Lopez Santi
NANicolás Aquino
Nicolás Aquino
ELEzequiel Lerech
Ezequiel Lerech
FBFernando Botto
Fernando Botto
Background: The correct management of lipid-lowering treatment is one of the key factors for the reduction of cardiovascular risk in secondary prevention patients. High-dose statins, ezetimibe, and more recently PCSK9 inhibitors (PCSK9i) are the main tools available to meet LDL cholesterol (LDL-C) therapeutic goals in these patients. Despite the overwhelming evidence in their favor, these therapies are greatly underutilized worldwide, with low levels of adherence and therapeutic inertia. In Argentina, there is scarce evidence on the quality of lipid-lowering treatment and the rate of patients in secondary prevention with a controlled lipid profile according to national and international guidelines. Methods: A prospective, multicenter, cross-sectional study including consecutive patients in secondary prevention for cardiovascular events from hospitals of Argentina with a Medical Residency system affiliated to CONAREC, was carried out from March to August 2020. Data was collected on the lipid-lowering treatment received, the reasons behind the non-use of statins in adequate doses and the lipid profile levels in case of having a record from the last 6 months prior to inclusion. Results: Among 1000 consecutive patients included from 24 centers corresponding to 11 provinces, 85.9% was treated with statins, 4.8% with ezetimibe, 2.4% with fibrates, and 13% was without treatment. In the case of patients treated with statin therapy, 67% was receiving high-dose statins (58% of the total number of patients). A total of 509 patients presented LDL-C assessment within the last 6 months. Mean LDL-C was 94 (90.6-97.8) mg/dl, HDL cholesterol 41 (40.7-42.6) mg/dl, and triglycerides 151 (142.9-159.8) mg/dl. In 30% of cases, LDL-C was below the cut-off value of 70 mg/dl and in 16% below 55 mg/ dl. In 37% of patients, LDL-C was >100 mg/dl. Conclusions: In this multicenter secondary prevention study performed in Argentina, just over half of the patients presented high-dose statin treatment, with scarce use of ezetimibe. Undertreatment was reflected in LDL-C values, with more than two-thirds of patients outside the therapeutic range, and therefore far from clinical guideline recommendations. How to cite this article: Sigal AR, Antoniolli M, López Santi P, Aquino N, Lerech E, Botto F, et al. Use of Lipid-Lowering Agents and Therapeutic Goal Achievement in Cardiovascular High-Risk Patients in Argentina. Rev Argent Cardiol 2021;89:373-383 http://dx.doi.org/10.7775/rac.v89.i5.20409

3 February 2026 in Revista Argentina de Cardiologia
Verified
Journal Article
Open access
PDF file
DCDiego Crippa
Diego Crippa
GTGiuliana A. Tresenza
Giuliana A. Tresenza
MAMelisa Antonioili
Melisa Antonioili
ELEzequiel D. Lerech
Ezequiel D. Lerech
JGJuan Gagliardi
Juan Gagliardi
HIHeraldo A. D` Imperio
Heraldo A. D` Imperio
Background: Delirium is a common and potentially preventable complication in the postoperative period following cardiovascular surgery (CVS). Its onset is associated with poorer clinical outcomes, such as longer hospital length of stay and higher mortality.Internationally, delirium in the postoperative context of cardiovascular surgery has been extensively studied in multicenter cohorts and observational studies, with varying prevalences. In Argentina, we have previous registries of CVS, but despite this, this complication has not been explored in depth. Objective: The aim of this study was to analyze the incidence of postoperative delirium following CVS and to identify predictors thatcontribute to its development.Methods: We conducted an analysis of the Argentine National Registry of Cardiovascular Surgery (ARGEN-CCV), a cross-sectional, multicenter study spanning 13 months from July 2021 to August 2022. Patients were recruited from 48 public and private cent-ers. Data from consecutive patients aged 18 years or older admitted for central CVS were analyzed. Surgeries for congenital heart defects and peripheral vascular surgery were excluded from the registry. The diagnosis of delirium was based on clinical assessment. Univariate and multivariate analyses were performed to define independent predictors of delirium onset.Results: A total of 1515 patients were included in the analysis with an incidence of delirium of 9.1%. Patients with delirium wereolder (68 vs. 64 years, p<0.001) and had a higher prevalence of chronic obstructive pulmonary disease (COPD), alcoholism, and frailty, as well as a higher incidence of postoperative atrial fibrillation (AF). On multivariate analysis, coronary artery disease (OR1.64; 95% CI: 1.02–2.64; p=0.041), postoperative sepsis (OR 3.13; 95% CI: 1.65–5.96; p<0.001), postoperative AF (OR 2.07; 95% CI: 1.29–3.32; p=0.003), and prolonged mechanical ventilation (OR 2.86; 95% CI 1.68–4.86; p<0.001), were identified as independent predictors of delirium, while frailty showed a trend (OR 2.16; p=0.068). A predictive model was constructed using these variables,which demonstrated good discrimination, with an area under the curve (AUC) of 0.76 (95% CI: 0.71–0.80) and excellent calibration (Hosmer-Lemeshow test with p value = 0.999).Conclusions: Postoperative delirium occurs in 9.1% of patients undergoing cardiovascular surgery in our series. Coronary arterydisease, postoperative AF, and prolonged MV were identified as predictors for the development of delirium.